BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aresbank Strengthens Trade Finance and Correspondent Banking Compliance with SymphonyAI8.10.2026 09:55:00 CEST | Press release
Specialist corporate bank connecting Europe, Middle East and North Africa, adopts a platform built to scale as regulations and trade volumes evolve As a specialized corporate and trade finance bank in the MENA region, Aresbank manages risk and moves money across some of the most sensitive trade corridors between Europe, the Middle East and North Africa. Operating in a highly regulated environment, Aresbank turned to SymphonyAI, a global leader in Vertical AI whose financial crime compliance platform already spans retail, commercial and correspondent banking, to strengthen its transaction monitoring framework across trade finance and correspondent banking. Headquartered in Madrid, the bank's business centers on trade instruments, including correspondent banking, documentary credits, international guarantees and multi-currency credit lines that connect European and MENA markets. Correspondent banking carries a distinct risk profile, and trade finance flows in the region remain a focus fo
Fortune Media and Great Place To Work Name Experian As One Of The ‘100 Best Companies to Work For Europe’ in 2026 for Second Year8.10.2026 09:00:00 CEST | Press release
Great Place To Work® and Fortune Europe have recognised Experian as one of the Fortune 100 Best Companies to Work For™ Europe for the second-year running. The 100 Best Companies to Work For Europe list is a comprehensive recognition for business excellence and employee experience, based on Great Place To Work’s proprietary Trust Index™ Survey. Great Place To Work evaluates confidential feedback from employees, validating against HR data from participating companies. Only companies with consistently high survey responses from employees — regardless of their role, department, or status in the company — are honored with placement on the list. Eligible companies have 500 or more employees and were represented on at least one national Best Workplaces™ List in Europe. Jacky Simmonds, Chief People Officer, Experian, said: “We are thrilled to being named one of the Fortune 100 Best Companies to Work For™ in Europe for the second year in a row. It’s an incredibly proud moment for us at Experian
Value Group Brings Its Integrated Global IROPS Management Model to the World Aviation Festival8.10.2026 08:32:00 CEST | Press release
Value Group, a leading provider of integrated aviation disruption management solutions, returns to the World Aviation Festival as a Gold Sponsor, reinforcing its role in the evolution of airline disruption management. From 13 to 15 October at FIL in Lisbon, the event is one of the aviation industry’s leading international technology conferences and exhibitions, bringing together airlines, airports and travel technology companies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007885823/en/ Thomas Sergnese, Co-CEO & Chief Commercial Officer and Daniele Bocchieri, Co-CEO & Chief Operating Officer At stand 1-180, Value Group will showcase the evolution of its integrated disruption management model and the RUBIK digital ecosystem, demonstrating how technology, operations and governance can work together as one connected system to manage irregular operations more effectively at both global and local level. Over the p
Colruyt Group Crosses the 150 Store Milestone With Rollout of Toshiba ELERA® Self Service Store Deployments8.10.2026 07:30:00 CEST | Press release
Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium Toshiba Global Commerce Solutions today announced the successful deployment of its ELERA® Self Service solution across 144 Colruyt Group stores: Okay, Okay City, Spar Colruyt Group and Bio-Planet. Today, 454 self-checkout systems have already been installed year-to-date across 150 stores. The project continues to expand, with an additional 51 stores planned in 2026 and further rollout in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007465701/en/ Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium. The deployment was designed to support a fast, intuitive, and customer-friendly checkout experience, while maintaining the personal interaction that remains important within the convenience retail environment. Across the
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older8.10.2026 07:00:00 CEST | Press release
New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1 Additional long-term data further demonstrate Nemluvio’s consistent safety profile and sustained efficacy, including improvements in skin clearance, itch, sleep and quality of life in adults with prurigo nodularis up to 148 weeks, and people with atopic dermatitis aged 12 and older up to 152 weeks2,3 Phase II pediatric data will also be presented, with nemolizumab driving meaningful and sustained improvements in children aged 2-11 years with moderate-to-severe atopic dermatitis4 Alongside a product theatre exploring how targeted IL-31 treatment may impact patient outcomes, these findings reinforce Galderma's leadership in advancing treatment goals in atopic dermatitis and prurigo nodularis Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new da
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom